PMDA Medical Device Registration in Japan: The Complete Guide

Japan is the world's fourth-largest medical device market, valued at over $30 billion annually. For foreign manufacturers, gaining market access requires navigating a regulatory system that is thorough, well-structured, and distinctly different from both the FDA and EU MDR frameworks. At the center of that system is the Pharmaceuticals and Medical Devices Agency (PMDA) — Japan's scientific review body for medical devices, pharmaceuticals, and regenerative medicine products.

This guide provides a comprehensive, practical overview of the PMDA medical device registration process, covering the regulatory framework, device classification, approval pathways, QMS requirements, clinical trial rules, and the specific challenges foreign manufacturers face when entering the Japanese market.

Japan's Regulatory Framework: Key Organizations

Three organizations share responsibility for medical device regulation in Japan:

PMDA (Pharmaceuticals and Medical Devices Agency)

PMDA is an independent administrative agency that conducts scientific reviews of medical device applications, provides regulatory consultation services, and manages post-market safety surveillance. PMDA reviews both Shonin (pre-market approval) applications and clinical trial protocols. Think of PMDA as functionally similar to FDA's CDRH — it is the technical review body, but it does not issue final regulatory decisions.

MHLW (Ministry of Health, Labour and Welfare)

The MHLW is the government ministry that issues the actual regulatory approvals and sets policy. After PMDA completes its scientific review and issues a favorable recommendation, the MHLW grants the formal Shonin (approval) or Ninsho (certification). MHLW also publishes the ordinances that govern QMS requirements, classification rules, and clinical trial standards.

Prefectural Governments

Japan's 47 prefectures handle Class I device notifications (Todokede) and conduct local manufacturing facility inspections. They also manage business licensing for manufacturers and distributors operating within their jurisdictions.

This three-tier structure means that the entity reviewing your technical dossier (PMDA), the entity granting your approval (MHLW), and the entity inspecting certain facilities (prefectural government) may all be different — a distinction foreign manufacturers must understand from the outset.

Device Classification in Japan

Japan classifies medical devices into four classes based on risk, aligned conceptually with the Global Harmonization Task Force (GHTF) framework:

Class	Risk Level	GHTF Equivalent	Regulatory Pathway	Examples
Class I	Lowest risk	GHTF Class A	Todokede (Notification)	Surgical gauze, tongue depressors, manual stethoscopes
Class II	Low-moderate risk	GHTF Class B	Ninsho (Third-Party Certification)	Powered wheelchairs, electronic thermometers, dental alloys
Class III	Moderate-high risk	GHTF Class C	Shonin (PMDA/MHLW Approval)	Dialysis equipment, ventilators, infusion pumps
Class IV	Highest risk	GHTF Class D	Shonin (PMDA/MHLW Approval)	Pacemakers, drug-eluting stents, artificial hearts

Key classification distinctions

• Class I devices require only a notification (Todokede) filed with the prefectural government. No PMDA review is involved.
• Class II devices that conform to a published certification standard (Ninsho Kijun) can be reviewed by a Registered Certification Body (RCB) — Japan's equivalent of an EU Notified Body. This is the Ninsho pathway.
• Class II devices without a certification standard, and all Class III and Class IV devices, must go through the full Shonin (pre-market approval) pathway, which involves PMDA scientific review followed by MHLW approval.

The classification of a specific device is determined by MHLW's classification catalogue (Ippan-teki Meisho). Each generic device name in the catalogue is assigned a class and, where applicable, a certification standard. Foreign manufacturers should verify classification early, as a device classified as Class II in the FDA system may fall into Class III or IV in Japan.

The Three Regulatory Pathways

1. Todokede (Notification) — Class I

The simplest pathway. The Marketing Authorization Holder (MAH) submits a notification to the relevant prefectural government. No PMDA review or clinical data is required. The notification includes basic product information, labeling, and the MAH's business license details. Processing typically takes 1-3 months.

2. Ninsho (Third-Party Certification) — Class II

For Class II devices that match a published certification standard, the MAH submits an application to a Registered Certification Body (RCB). The RCB reviews the technical documentation against the certification standard and, if the device conforms, issues a certification. PMDA is not directly involved in individual Ninsho reviews.

Key requirements:

• The device must fit within a published Ninsho Kijun (certification standard)
• The MAH must hold a valid QMS certificate (MHLW Ordinance 169)
• Technical documentation must demonstrate conformance to the standard
• Processing typically takes 6-10 months

There are currently 14 RCBs operating in Japan. Selecting an RCB with experience in your specific product category can significantly affect review timelines.

3. Shonin (Pre-Market Approval) — Class II (no standard), III, IV

The Shonin pathway is the most rigorous and is required for all high-risk devices and any Class II device that lacks a Ninsho Kijun. This is the pathway most foreign manufacturers will encounter for innovative or higher-risk products.

The Shonin Approval Process: Step by Step

Step 1: Pre-Submission Consultation with PMDA

PMDA offers formal pre-submission consultations (Taimen Joshu) that are strongly recommended — and in practice, nearly essential for Class III and IV devices. These paid consultations allow the applicant to discuss:

• Device classification confirmation
• Clinical data requirements and study design
• Non-clinical testing requirements
• QMS compliance strategy

PMDA consultation fees are structured by device class and consultation type. Scheduling can take 2-4 months, so early engagement is critical.

Step 2: Prepare the Technical Dossier (STED Format)

Japan accepts the Summary Technical Documentation (STED) format developed by the GHTF (now IMDRF). The STED dossier includes:

• Device description and specifications
• Design verification and validation data
• Biocompatibility testing (per ISO 10993, with PMDA-specific considerations)
• Electrical safety and electromagnetic compatibility (per IEC 60601 series, where applicable)
• Software documentation (per IEC 62304, if applicable)
• Sterilization validation (per ISO 11135/11137, if applicable)
• Clinical evidence (clinical trial data, literature review, or both)
• Labeling and instructions for use (in Japanese)
• Risk management file (per ISO 14971)

All documentation submitted to PMDA must be in Japanese. Translation quality is critical — PMDA reviewers will scrutinize technical terminology, and poor translations can trigger unnecessary review questions and delays.

Step 3: QMS Inspection Application

Before or concurrent with the Shonin application, the MAH must apply for a QMS conformity inspection. PMDA conducts QMS audits against MHLW Ordinance 169 (discussed in detail below). For foreign manufacturers, this involves an on-site inspection at the manufacturing facility.

Step 4: Submit the Shonin Application

The MAH submits the complete application package to PMDA. The package includes:

• The STED technical dossier
• QMS-related documentation
• Proof of Foreign Manufacturer Registration (FMR/DMAL)
• Application forms and fees

PMDA conducts a formal acceptance check. If the application is incomplete, PMDA will issue a request for additional information before formal acceptance.

Step 5: PMDA Scientific Review

PMDA assigns reviewers who conduct a detailed technical evaluation. This phase typically involves multiple rounds of questions and responses between PMDA and the applicant. For complex devices, the review may include:

• Expert panel consultations
• Requests for additional non-clinical or clinical data
• Label review and revision

The review timeline varies significantly by device class and complexity:

• Class II (Shonin): 9-14 months
• Class III: 12-18 months
• Class IV: 14-24 months

These timelines represent PMDA review time only and do not include applicant response time, which can add months or years.

Step 6: MHLW Approval

Upon completion of PMDA's review and a favorable recommendation, the application is forwarded to MHLW for formal approval. MHLW's review is primarily administrative and typically takes 1-2 months.

Step 7: NHI Reimbursement Listing (If Applicable)

For devices intended for use in Japan's National Health Insurance (NHI) system, a separate application for reimbursement listing is required after Shonin approval. NHI pricing can take an additional 2-6 months and is a critical factor in commercial viability.

JPAL: The Legal Foundation

The Pharmaceutical and Medical Device Act (PMD Act, commonly referred to by its historical abbreviation JPAL — Japan Pharmaceutical Affairs Law) is the primary legislation governing medical devices in Japan. Originally enacted in 1960 and substantially revised in 2005 and 2014, the PMD Act establishes:

• The classification system and regulatory pathways
• Requirements for Marketing Authorization Holders (MAH)
• QMS requirements (implemented through MHLW ordinances)
• Post-market surveillance obligations
• Penalties for non-compliance

The 2014 revision was particularly significant: it introduced the separate regulatory category for regenerative medicine products, streamlined the Ninsho pathway, and updated post-market surveillance requirements. Foreign manufacturers should ensure their regulatory strategy is aligned with the current PMD Act framework, not older JPAL-era guidance.

QMS Requirements: MHLW Ordinance 169

Japan's QMS requirements are codified in MHLW Ministerial Ordinance No. 169 (often called the "QMS Ordinance"). This ordinance is Japan's adaptation of ISO 13485, with Japan-specific additions. Compliance with ISO 13485 alone is not sufficient — manufacturers must demonstrate conformity to Ordinance 169 specifically.

Key differences between Ordinance 169 and ISO 13485

Requirement	ISO 13485:2016	MHLW Ordinance 169
Scope	International standard	Japanese regulatory requirement
Biological safety	Referenced via ISO 10993	Additional PMDA-specific biological safety requirements
Design control records	Required	Required with enhanced traceability to Japanese labeling requirements
Management review	Required	Required with specific elements for Japanese regulatory reporting
CAPA documentation	Required	Required with mandatory reporting thresholds for Japanese adverse event criteria
Sterilization	Referenced via ISO standards	Additional requirements for specific sterilization methods common in Japan
Post-market surveillance	General requirement	Detailed integration with PMDA's post-market safety reporting framework

QMS Inspection Process

PMDA conducts QMS inspections as part of the Shonin approval process. For foreign manufacturers, this means PMDA inspectors will visit the overseas manufacturing facility. Key aspects:

• Inspection scope: Manufacturing processes, design controls, CAPA, complaint handling, supplier management
• Inspection team: Typically 3-5 PMDA inspectors, often accompanied by a translator
• Duration: 2-5 days on-site
• Frequency: Initial inspection for Shonin approval; periodic re-inspections every 5 years for renewal
• Common findings: Inadequate Japanese-language documentation, insufficient traceability of design changes, gaps in post-market surveillance procedures specific to Japan

Manufacturers with ISO 13485 certification from a recognized certification body may qualify for a simplified QMS review (document-based review without on-site inspection) for some device classes. However, this is not guaranteed — PMDA retains discretion to require on-site inspection regardless.

Clinical Trial Requirements in Japan

Clinical trial requirements depend on device classification and the availability of existing clinical evidence.

When clinical trials are required

• Class I and most Class II: No clinical trial required. Performance testing and literature review are typically sufficient.
• Class III and IV (novel devices): Clinical trials are generally required, particularly for devices with novel technology, new intended uses, or where existing clinical evidence is insufficient.
• Devices with predicate equivalence: If a substantially equivalent device (Shonin-acquired predicate) exists in Japan with adequate clinical data, a clinical trial may be avoidable through a clinical evaluation report.

Clinical trial regulations

Clinical trials for medical devices in Japan are governed by the GCP Ordinance for Medical Devices (MHLW Ordinance No. 36). Key requirements:

• Clinical trial notification (CTN): The sponsor must submit a CTN to PMDA at least 30 days before initiating the trial.
• IRB approval: Required from each participating institution's Institutional Review Board.
• PMDA consultation: Pre-trial consultation with PMDA is strongly recommended to align on study design, endpoints, and sample size.
• Monitoring and source data verification: Required per Japan GCP standards, which are broadly aligned with ICH E6 but include Japan-specific requirements.
• Foreign clinical data: PMDA has progressively increased acceptance of foreign clinical data, particularly data from global multi-center trials that include Japanese sites. However, standalone foreign clinical data may not be accepted for novel Class III/IV devices. Japan-specific bridging studies or supplemental Japanese patient data may be required.

Acceptance of foreign clinical data

This is a nuanced and evolving area. PMDA's general position:

• Multinational data with Japanese sites: Preferred and most likely to be accepted without additional requirements.
• Foreign data only (no Japanese patients): May be accepted for lower-risk devices or where clinical outcomes are not expected to differ across ethnic populations. For higher-risk devices, PMDA frequently requests Japan-specific data or a bridging analysis.
• Ethnic sensitivity analysis: PMDA may require analysis demonstrating that clinical outcomes are consistent across Japanese and non-Japanese patient populations.

Foreign Manufacturer Registration (DMAL Holder Requirements)

Foreign manufacturers cannot directly market medical devices in Japan. A Designated Marketing Authorization Holder (DMAL holder) — a Japanese legal entity — must serve as the responsible party for all regulatory submissions, post-market obligations, and product quality.

DMAL holder responsibilities

• Filing and maintaining Shonin/Ninsho/Todokede registrations
• Managing QMS compliance and PMDA inspections
• Handling adverse event reporting and field safety corrective actions
• Maintaining product master files and labeling
• Serving as the legal point of contact for MHLW and PMDA

Foreign Manufacturer Registration (FMR)

In addition to appointing a DMAL holder, foreign manufacturers must obtain Foreign Manufacturer Registration (Gaikoku Seizogyo-sha Nintei) from MHLW. This registration confirms that the foreign manufacturing facility meets Japan's QMS requirements. FMR is a prerequisite for Shonin submission.

Selecting a DMAL holder

This is one of the most consequential decisions for foreign manufacturers entering Japan. Options include:

1. Japanese subsidiary: Maximum control but requires significant investment in Japanese regulatory, quality, and commercial infrastructure.
2. Japanese distributor as DMAL: Common approach, but creates a dependency — the distributor holds the regulatory approval and can potentially restrict manufacturer flexibility.
3. Specialized regulatory services firm: Some firms act as DMAL holders for multiple foreign manufacturers, providing regulatory expertise without the distributor dependency. This is increasingly popular for market entry.

Comparison: PMDA vs FDA vs EU MDR

Aspect	PMDA (Japan)	FDA (USA)	EU MDR
Competent authority	MHLW (approval) / PMDA (review)	FDA / CDRH	National Competent Authorities
Classification	4 classes (I-IV)	3 classes (I-III)	4 classes (I, IIa, IIb, III)
Lowest-risk pathway	Todokede (notification)	Exempt / 510(k)	Self-declaration (Class I)
Mid-risk pathway	Ninsho (RCB certification)	510(k) / De Novo	Notified Body certification
Highest-risk pathway	Shonin (PMDA + MHLW)	PMA	Notified Body + Scrutiny procedure
QMS standard	MHLW Ordinance 169 (ISO 13485+)	21 CFR 820 (QMSR/ISO 13485)	ISO 13485 (harmonized standard)
Clinical trial regulation	GCP Ordinance No. 36	IDE (21 CFR 812)	ISO 14155 / MDR Article 82
Local representative required	DMAL holder (Japanese entity)	U.S. Agent	Authorized Representative (EC REP)
Language	Japanese (mandatory)	English	Official language of member state
UDI system	Japan UDI (MHLW)	FDA GUDID	EU UDI / EUDAMED
Approval validity	5 years (renewable)	Indefinite	5 years (CE certificate)
Post-market surveillance	PMDA safety reporting	FDA MDR / MedWatch	Vigilance reporting / PSUR
Reimbursement linkage	NHI pricing (separate process)	CMS (separate)	Member state-specific

Timeline Estimates by Device Class

Device Class	Pathway	Typical Timeline (Total)	Key Variables
Class I	Todokede	1-3 months	Completeness of notification, prefectural processing speed
Class II (with standard)	Ninsho	6-12 months	RCB workload, QMS audit scheduling, conformance to Ninsho Kijun
Class II (no standard)	Shonin	12-20 months	PMDA review complexity, QMS inspection, number of review question rounds
Class III	Shonin	14-26 months	Clinical data requirements, PMDA consultation outcomes, QMS inspection logistics
Class IV	Shonin	18-36 months	Clinical trial duration, expert panel review, complexity of technology

Important notes on timelines:

• Timelines above include PMDA review time but exclude clinical trial duration (which can add 1-4 years for Class III/IV devices requiring Japan-specific data).
• Applicant response time to PMDA review questions is typically the single largest variable. Responses taking 3-6 months per round are common.
• QMS inspection scheduling for overseas facilities can add 3-6 months due to PMDA inspector availability and travel logistics.
• NHI reimbursement listing (if needed) adds 2-6 months after Shonin approval.

Common Pitfalls for Foreign Manufacturers

1. Underestimating translation requirements

All submissions to PMDA must be in Japanese. This is not a formality — PMDA reviewers work exclusively in Japanese, and poor translations generate review questions, extend timelines, and can fundamentally misrepresent the product's technical characteristics. Invest in regulatory-specialized translation services, not general-purpose translators.

2. Assuming ISO 13485 equals QMS compliance

ISO 13485 certification is necessary but not sufficient. MHLW Ordinance 169 includes Japan-specific requirements that go beyond ISO 13485. Manufacturers who assume their existing QMS certificate covers Japan requirements frequently face findings during PMDA inspections.

3. Choosing the wrong DMAL holder

A DMAL holder who lacks regulatory experience with your device type, or whose commercial interests conflict with yours, can delay approvals and limit your strategic flexibility in the Japanese market. Conduct thorough due diligence before signing a DMAL agreement.

4. Ignoring pre-submission consultation

PMDA's Taimen Joshu consultations are technically optional but practically essential for Class III/IV devices. Skipping them risks misaligned clinical development strategies, incorrect classification assumptions, and avoidable review delays.

5. Misclassifying the device

A device classified as Class II by the FDA may be Class III or IV in Japan. Classification determines the entire regulatory pathway, timeline, and cost. Verify classification against MHLW's Ippan-teki Meisho catalogue early in your planning.

6. Underestimating clinical data expectations

PMDA's clinical evidence requirements for Class III/IV devices can be more specific than FDA's — particularly regarding ethnic sensitivity and Japan-specific patient data. Manufacturers who plan global clinical programs without considering Japan's requirements often face costly protocol amendments or supplemental studies.

7. Neglecting post-market obligations

Japan has robust post-market surveillance requirements, including periodic safety reports, adverse event reporting, and re-examination studies for novel devices. These obligations fall on the DMAL holder but ultimately require manufacturer cooperation. Failure to comply can result in suspension or revocation of the Shonin approval.

8. Overlooking NHI reimbursement strategy

Regulatory approval without NHI reimbursement listing severely limits commercial viability in Japan, where over 70% of medical device spending flows through the NHI system. Reimbursement strategy should be developed in parallel with regulatory planning, not as an afterthought.

Regulatory Changes and Monitoring

Japan's regulatory environment for medical devices continues to evolve. Recent and ongoing developments include:

• Expansion of Ninsho certification standards: MHLW continues to publish new Ninsho Kijun, expanding the range of Class II devices eligible for the faster RCB certification pathway.
• PMDA's international reliance initiatives: PMDA is increasingly participating in international regulatory convergence efforts through IMDRF, including mutual recognition of QMS audits and acceptance of foreign clinical data.
• Software as a Medical Device (SaMD): PMDA has published dedicated guidance for AI/ML-based and software-only devices, an area of active regulatory development.
• Post-market surveillance reform: Ongoing refinements to adverse event reporting thresholds and post-market study requirements.

Tracking these changes is critical for manufacturers with products on the Japanese market or in the registration pipeline. A classification change, a new Ninsho Kijun, or a revised clinical data policy can materially affect your regulatory strategy and timeline.

Conclusion

Japan's PMDA registration system is rigorous, well-structured, and rewarding for manufacturers who invest in understanding its requirements. The four-class system, the distinction between Shonin and Ninsho pathways, the DMAL holder structure, and the Japan-specific QMS requirements under Ordinance 169 all create a pathway that is substantively different from the FDA or EU MDR frameworks. Success requires early classification verification, strategic DMAL holder selection, Japanese-language regulatory documentation, and a clinical evidence strategy that accounts for PMDA's expectations regarding Japan-specific patient data.

---

Japan's PMDA publishes regulatory updates, new certification standards, classification changes, and clinical guidance on a rolling basis. MedFlux monitors 27 regulators in real time — including PMDA and MHLW — so your regulatory team has immediate visibility into every change that could affect your Japan market access strategy or existing product registrations.